Mineralys Therapeutics, Inc. (MLYS) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-12
How it makes money
It has not generated any revenue since its inception and depends entirely on successfully developing and commercializing its sole product candidate, lorundrostat.
The company operates as a clinical-stage biopharmaceutical enterprise focused on cardiorenal conditions. It has no approved products on the market and relies completely on future regulatory approvals to begin commercial sales.
Management submitted a new drug application to the FDA for lorundrostat as an add-on treatment for hypertension, with a target action date set for December 22, 2026.
What protects it: the moat
It relies on intellectual property protection for lorundrostat, which it originally licensed from Tanabe Pharma Corporation.
Management asserts that its competitive position rests on establishing an intellectual property portfolio around its proprietary aldosterone synthase inhibitor.
However, because the company licensed the foundational compound from Tanabe Pharma Corporation, its long-term exclusivity depends heavily on the strength and defensibility of those in-licensed patents.
What growth costs
It incurs substantial ongoing operating losses driven by research, clinical trials, and general administrative expenses.
The business burns significant capital to fund clinical development programs, such as its pivotal trials and extension studies for hypertension, chronic kidney disease, and obstructive sleep apnea.
Net losses were $154.7 million for the year ended December 31, 2025, and $177.8 million for the year ended December 31, 2024, bringing its accumulated deficit to $457.2 million as of December 31, 2025.
What could damage it
If regulatory approval for lorundrostat is delayed or denied by the FDA, the company may fail to generate revenue and could be forced to curtail operations.
The enterprise is entirely dependent on the commercial prospects of a single product candidate. If the FDA rejects the new drug application or requires prolonged additional trials following the target action date, the company will lack incoming cash flows.
Without commercial revenue or sufficient external financing, management would be forced to delay or terminate its development programs, permanently impairing its financial condition.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.